Effect of a 2-week Sugar Stress on Bacterial Profiles in Whole Saliva
NCT ID: NCT04199897
Last Updated: 2021-10-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2020-05-05
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study is to investigate the bacterial profiles in whole saliva before and after a 2-week sugar provocation with and without probiotic supplements in healthy young adults. A second aim is to study the bacterial profiles 3 weeks after the termination of the sugar stress. The null hypothesis are:
1. Sucrose-induced stress does not affect the bacterial profiles in whole saliva compared with stress induced by a non-fermentable pentitol (xylitol)
2. The intake of lactobacilli-derived probiotic bacteria does not affect the sugar-induced changes in the bacterial profiles in whole saliva when compared with placebo
3. The bacterial profiles in saliva do not differ from baseline 3 weeks after the termination of the intervention.
Material The study group will consist of 80 young adults with uncompromised oral health that volunteer after informed consent. The inclusion criteria are i) over 18 years with more than 20 own natural teeth, ii) no chronic systemic diseases affecting salivary functions, iii) no medication except for contraceptives, and iv) being a non-smoker. The project will be submitted for ethical approval.
Study design The study will employ a randomized triple-blind, placebo controlled design with four parallel arms as shown in Figure 1. The group allocation will be arranged through computer-generated envelopes and concealed for all parts (subjects, investigators, laboratory staff). After the baseline registration (Day 0), the participants are asked to rinse their mouth with 10 mL of a sucrose- or xylitol-containing solution every second hour (7-8 times per day) during 14 days (day 14). The solution should be "swished" around and between the teeth for at least 30 seconds and then spitted out. No after-rinsing with water is allowed. In addition, the subjects are provided with tablets containing either probiotic lactobacilli or placebo for daily use during the 14-day rinsing period. The participants will be thoroughly instructed to maintain their normal eating and drinking habits as well as their daily oral hygiene procedures.
Intervention - probiotics and placebo The active and placebo lozenges for the 14-day intervention period will be distributed to the participants after baseline examination and sampling. The active lozenges contain two strains of probiotic bacteria; Lactobacillus rhamnosus PB01 (DSM 14869) and Lactobacillus curvatus EB10 (DSM 32307) at a concentration of 109 colony forming units each. The tablets have previously been used in a randomized controlled trial with gingival inflammation and microbial endpoints (Keller et al., 2018). The full composition is shown in Appendix X. The placebo lozenges have an identical composition, except for the bacteria, with the same size and taste. The participants are instructed to let one tablet slowly dissolve in the mouth two times per day (morning, evening) after regular tooth brushing. They are also required to keep a daily logbook covering the sugar rinses and tablet intakes and to return non-consumed tablet at the first follow-up. The sugar rinses will be prepared and distributed in non-marked bottles and the participants will be supplied with a dose spoon indicating 10 mL. The participants will also be given a standardized fluoride toothpaste for use during the entire study. An independent monitor at Copenhagen University will guarantee the allocation concealment.
Clinical examination and saliva samplings At baseline, a clinical examination is performed by one experienced and calibrated dentist. No radiographs are exposed. The following variables are registered: a) caries experience, expressed as decayed, missed and filled teeth (DMFT), b) the amount of supragingival plaque (s-PI), c) the level of gingival inflammation (s-GI), and d) bleeding-on-probing (s-BOP). The PI, GI and BOP will be scored in a simplified manner on six pre-selected teeth and re-evaluated at the follow-ups after 14 and 35 days. Stimulated whole saliva samples (approximately 1.0 mL) will be collected at baseline and after 14 and 35 days in a standardized way by one trained investigator. All samples are stored at -80°C until further processing.
Laboratory procedures The DNA will be extracted using a Pathogen\_Universal\_200 protocol (Roche) in accordance with the manufacturer's guidelines at the Institute for Inflammatory Research, Rigshospitalet, København, Danmark. The profiles of the salivary microbiome will be analysed with Next Generation Sequencing (NGS) and qPCR as preciously described (Keller et al., 2018).
Endpoints Salivary bacterial profiles will be analyzed by means of the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) in co-operation with the Costerton Center at University of Copenhagen. Secondary endpoints are simplified plaque index (PI), gingival index (GI) and bleeding-on-probing (BOP) as scored after 15 and 35 days.
Statistical methods All data will be checked for normality and processed with the IBM-SPSS software. Clinical data are compared using the Freidman test with Dunn's comparison. Relative abundance of bacterial DNA reads are compared between groups of samples at genus and species level using the Kruskal-Wallis and Mann-Whitney tests with Benjamini-Hochberg correction for multiple dependent analyses. P-values less than 0.05 will be considered statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group (sucrose + probiotics)
Sucrose rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
Succrose rinsing
Sucrose rinsing 7-8 times a day for 14 days
Probiotic lozenges
Probiotic lozenges 2 times a day for 35 days
Intervention group (sucrose + placebo
Sucrose rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
Succrose rinsing
Sucrose rinsing 7-8 times a day for 14 days
Placebo tablets
Placebo lozenges 2 times a day for 35 days
Control group (xylitol + probiotics)
Xylitol rinsing 8 times a day for 14 days Probiotic lozenges 2 times a day for 25 days
Probiotic lozenges
Probiotic lozenges 2 times a day for 35 days
xylitol rinsing
Xylitol rinsing 7-8 times a day for 14 days
Control group (xylitol + placebo
Xylitol rinsing 8 times a day for 14 days Placebo lozenges 2 times a day for 25 days
xylitol rinsing
Xylitol rinsing 7-8 times a day for 14 days
Placebo tablets
Placebo lozenges 2 times a day for 35 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Succrose rinsing
Sucrose rinsing 7-8 times a day for 14 days
Probiotic lozenges
Probiotic lozenges 2 times a day for 35 days
xylitol rinsing
Xylitol rinsing 7-8 times a day for 14 days
Placebo tablets
Placebo lozenges 2 times a day for 35 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no chronic systemic diseases affecting salivary functions
* no medication except for contraceptives
* non-smoker
Exclusion Criteria
* systemic antibiotics within the latest 3 months
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Copenhagen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniel Belstrøm, DDS, PhD
Associate professor, Principal Investiator, dr. odont., PhD, DDS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Copenhagen, Dept. of Odontology
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UCPH_OI_004
Identifier Type: -
Identifier Source: org_study_id